News

Read our latest news, and find more about us and our portfolio companies.

2021/02/24
Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline

• Deal led by Rock Springs Capital and joined by Bain Capital Life Sciences, Deerfield Management, RA Capital Management and other investors • Proceeds will advance XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4) into the clinic • Two investigational new drug (IND) applications planned in 2021

2021/02/11
Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients

* Artios Pharma transitions to a clinical-stage precision medicine company * Advances next generation DNA Damage Response (DDR) treatment targeting ATR in patients with advanced or metastatic solid tumors

2021/01/21
Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders

Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders - Company also announces appointment of biotech veteran Mike Grey as Chairman of the Board